top of page
  • Writer's picturePlaqueTec

PlaqueTec wins MedTech Company of the Year at the Cambridge Independent Science and Technology Awards 2024

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has received the Award for MedTech Company of the Year at this year's Cambridge Independent Science and Technology Awards, in recognition of the Company's recent progress towards improving outcomes for patients with coronary artery disease.

PlaqueTec is pioneering a precision medicine approach for coronary artery disease. At the heart of its strategy lies BioCarta – a bioinformatics platform that correlates in vivo biomarkers localising at the site of coronary plaque, with other critical patient factors such as clinical phenotype, genotype, systemic biochemistry, and intracoronary imaging. BioCarta is powered by PlaqueTec’s novel intracoronary blood sampling technology, the Liquid Biopsy System, which, when combined with extensive clinical trials data, holds the potential to define disease signals and identify new actionable drug targets to enable the development of personalised interventions that will revolutionise patient care.

The Cambridge Independent Science and Technology Awards recognise outstanding life science and biotechnology companies in Cambridge. The ceremony took place on 16th May 2024 at Hinxton Hall Conference Centre, on the world famous Wellcome Genome Campus in Cambridge, and was attended by businesses, organisations and research institutes from a broad range of sectors, from medtech to AI, biotech, and cleantech.

For more information about PlaqueTec, please visit:


Commenting has been turned off.
bottom of page